InsidersTradesSigma
Follow the Korro Bio, Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €190.1m. The latest transaction was filed on 8 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: FORMELA JEAN FRANCOIS. All data is free.
91
Insider Decl.
n/a
Thresholds
€27m
22 ops.
Buy Volume
€2m
27 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Korro Bio, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$20.20.
45Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 September 2026
Declarations91 total
7,347 shares@ US$13.5137CommonSEC144:0001959173-26-006800
249 shares@ US$13.960.0018% mcap0.1% of flowCommon StockSEC:0001030575-26-000012:0
51 shares@ US$13.960.0004% mcap0.0% of flowCommon StockSEC:0001030575-26-000012:1
249 shares@ US$13.730.0018% mcap0.1% of flowCommon StockSEC144:0001628280-26-059122
51 shares@ US$13.730.0004% mcap0.0% of flowCommon StockSEC144:0001628280-26-059121
23,584 shares@ US$14.000.16% mcap10.6% of flowCommon StockSEC:0001030575-26-000010:0
4,884 shares@ US$14.000.034% mcap2.2% of flowCommon StockSEC:0001030575-26-000010:1
23,584 shares@ US$13.220.15% mcap8.1% of flowCommon StockSEC144:0001628280-26-058030
4,884 shares@ US$13.220.032% mcap3.4% of flowCommon StockSEC144:0001628280-26-058029
1,775 shares@ US$13.960.013% mcap0.9% of flowCommon StockSEC:0001030575-26-000008:0
368 shares@ US$13.960.0026% mcap0.2% of flowCommon StockSEC:0001030575-26-000008:1
5,222 shares@ US$11.39980.030% mcap70.6% of flowCommon stock, $0.001 par value per shareSEC:0000902664-26-003434:0
Canonical exit: 4 Nov 2026 (T+90)
1,462 shares@ US$13.18690.0098% mcap22.9% of flowCommon stock, $0.001 par value per shareSEC:0000902664-26-003434:1
Canonical exit: 8 Nov 2026 (T+90)
1,775 shares@ US$13.490.012% mcap0.7% of flowCommon StockSEC144:0001628280-26-055858
368 shares@ US$13.490.0025% mcap0.3% of flowCommon StockSEC144:0001628280-26-055859
7,500 shares0Common StockSEC:0001193125-26-306733:0
5,500 shares0Common StockSEC:0001193125-26-306742:0
6,500 shares0Common StockSEC:0001193125-26-306739:0
7,500 shares0Common StockSEC:0001193125-26-306743:0
85,955 shares@ US$14.030.59% mcap45.4% of flowCommon StockSEC:0001030575-26-000006:0
14,745 shares@ US$14.030.10% mcap7.8% of flowCommon StockSEC:0001030575-26-000006:1
817 shares@ US$13.960.0056% mcap0.4% of flowCommon StockSEC:0001030575-26-000006:2
8,506 shares@ US$13.960.058% mcap4.5% of flowCommon StockSEC:0001030575-26-000006:3
25 of 91 declarations
关于 Korro Bio, Inc.
Korro Bio, Inc. 是一家生物制药公司，专注于开发基于RNA编辑的疗法。该公司在纳斯达克上市，股票代码为XNAS。